Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MARC SE-Africa

Financiado

Cerrado

Mitigating Antimalarial Resistance Consortium in South East Africa

BACKGROUND: Gains achieved in reducing the burden of malaria and advancing its elimination are now threatened by the independent emergence and local spread of artemisinin-resistant parasites in East Africa. Protecting the efficacy... ver más

31/03/2027

UCT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITY OF CAPE TOWN No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-31

HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01: Promoting implementation of researc... ExpectedOutcome:This topic aims at supporting activities that contribute to one or several of the ex...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

UCT

876.62K€ | Lider

LIVERPOOL SCHOOL OF TROPICAL...

793.46K€ | Participante

AIGHD Foundation

220.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GLOBALMED Artemisinin based combination therapy an illustration of th... 927K€ Cerrado

ReMVeC How has the rapid scale up of malaria control in Africa impa... 1M€ Cerrado

INTERMALTRAINING Intervention strategies against malaria 3M€ Cerrado

PDC2022-133085-I00 DESARROLLO DE UNA NUEVA GENERACION DE FARMACOS ANTIMALARICOS... 138K€ Cerrado

SAFIRE SAFETY OF ANTIMALARIALS IN THE FIRST TRIMESTER: AN ADAPTIVE... 5M€ Cerrado

SEMA ReACT SEvere MAlaria treatment with Rectal artesunate and Artemisi... 4M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-03-31
Fecha Fin: 2027-03-31

Líder del proyecto

UNIVERSITY OF CAPE TOWN No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto BACKGROUND: Gains achieved in reducing the burden of malaria and advancing its elimination are now threatened by the independent emergence and local spread of artemisinin-resistant parasites in East Africa. Protecting the efficacy of the current first-line malaria treatments, all of which are artemisinin-based, is now a top public health priority. OBJECTIVE: The Mitigating Antimalarial Resistance Consortium for South-East Africa (MARC SE-Africa) is designed to promote the translation of evidence of artemisinin and partner drug resistance of public health significance into policy and practice. METHODS: MARC SE-Africa brings together clinical researchers with experience in implementation research, experts in malaria chemotherapy and health policy, national malaria programmes and end users. Together we will improve estimates of antimalarial drug resistance and co-design a costed, Regional Detailed Action Plan to respond promptly to emerging antimalarial drug resistance. Dynamically-updated, evidence-based malaria treatment guidelines and graphic evidence summaries using MAGICapp will be developed, disseminated and evaluated. EXPECTED RESULTS: Predictive maps will better define antimalarial drug resistance for all eighteen South-East African malaria-endemic countries. We will expedite evidence sharing on antimalarial drug resistance with policy makers in at least eight countries. We will help at least four countries respond promptly and effectively to these results. We will facilitate the use of evidence on antimalarial resistance to inform better malaria treatment policies and will evaluate their uptake into clinical practice by primary healthcare workers in at least two countries. This will provide an evidence-based, reproducible model to mitigate the threat of antimalarial drug resistance and ensure sustained effective malaria treatment, including for the vulnerable communities that bear a disproportionately high burden of malaria and its sub-optimal treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores